Cox Terhorst

Cox Terhorst

Auto-generated profile, based on publicly available information

Cox Terhorst

Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2010 in Seminars in Immunopathology
Verified
Journal Article
Closed access
PDF file
CDCynthia Detre
Cynthia Detre
MKMarton Keszei
Marton Keszei
XRXavier Romero
Xavier Romero
GTGeorge C. Tsokos
George C. Tsokos
CTCox Terhorst
Cox Terhorst

22 August 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JYJuhan Yoon
Juhan Yoon
JLJuan Manuel Leyva-Castillo
Juan Manuel Leyva-Castillo
GWGuoxing Wang
Guoxing Wang
CGClaire Galand
Claire Galand
MOMichiko K. Oyoshi
Michiko K. Oyoshi
RGRaif S. Geha
Raif S. Geha
Atopic dermatitis (AD) is a Th2-dominated inflammatory skin disease characterized by epidermal thickening. Serum levels of IL-22, a cytokine known to induce keratinocyte proliferation, are elevated in AD, and Th22 cells infiltrate AD skin lesions. We show that application of antigen to mouse skin subjected to tape stripping, a surrogate for scratching, induces an IL-22 response that drives epidermal hyperplasia and keratinocyte proliferation in a mouse model of skin inflammation that shares many features of AD. DC-derived IL-23 is known to act on CD4+ T cells to induce IL-22 production. However, the mechanisms that drive IL-23 production by skin DCs in response to cutaneous sensitization are not well understood. We demonstrate that IL-23 released by keratinocytes in response to endogenous TLR4 ligands causes skin DCs, which selectively express IL-23R, to up-regulate their endogenous IL-23 production and drive an IL-22 response in naive CD4+ T cells that mediates epidermal thickening. We also show that IL-23 is released in human skin after scratching and polarizes human skin DCs to drive an IL-22 response, supporting the utility of IL-23 and IL-22 blockade in AD.

14 November 2020 in Cellular Immunology
Verified
Journal Article
Closed access
TBThais B. Bertolini
Thais B. Bertolini
MBMoanaro Biswas
Moanaro Biswas
CTCox Terhorst
Cox Terhorst
HDHenry Daniell
Henry Daniell
Roland W HerzogRoland W Herzog
Roland W Herzog
APAnnie R. Pineros
Annie R. Pineros

1 June 2013 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
XWXiaomei Wang
Xiaomei Wang
ASAlexandra Sherman
Alexandra Sherman
GLGongxian Liao
Gongxian Liao
KLKam W Leong
Kam W Leong
HDHenry Daniell
Henry Daniell
RHRoland W. Herzog
Roland W. Herzog

1 September 2019 in Cancer Immunology Research
Verified
Journal Article
Closed access
BYBurcu Yigit
Burcu Yigit
NWNinghai Wang
Ninghai Wang
EHElisa Ten Hacken
Elisa Ten Hacken
SCShih-Shih Chen
Shih-Shih Chen
ABAtul K. Bhan
Atul K. Bhan
CTCox Terhorst
Cox Terhorst
The tumor microenvironment in leukemia and solid tumors induces a shift of activated CD8+ cytotoxic T cells to an exhausted state, characterized by loss of proliferative capacity and impaired immunologic synapse formation. Efficient strategies and targets need to be identified to overcome T-cell exhaustion and further improve overall responses in the clinic. Here, we took advantage of the Eμ-TCL1 chronic lymphocytic leukemia (CLL) and B16 melanoma mouse models to assess the role of the homophilic cell-surface receptor SLAMF6 as an immune-checkpoint regulator. The transfer of SLAMF6+ Eμ-TCL1 cells into SLAMF6−/− recipients, in contrast to wild-type (WT) recipients, significantly induced expansion of a PD-1+ subpopulation among CD3+CD44+CD8+ T cells, which had impaired cytotoxic functions. Conversely, administering anti-SLAMF6 significantly reduced the leukemic burden in Eμ-TCL1 recipient WT mice concomitantly with a loss of PD-1+CD3+CD44+CD8+ T cells with significantly increased effector functions. Anti-SLAMF6 significantly reduced leukemic burden in the peritoneal cavity, a niche where antibody-dependent cellular cytotoxicity (ADCC) is impaired, possibly through activation of CD8+ T cells. Targeting of SLAMF6 affected tumor growth not only in B cell–related leukemia and lymphomas but also in nonhematopoietic tumors such as B16 melanoma, where SLAMF6 is not expressed. In vitro exhausted CD8+ T cells showed increased degranulation when anti-human SLAMF6 was added in culture. Taken together, anti-SLAMF6 both effectively corrected CD8+ T-cell dysfunction and had a direct effect on tumor progression. The outcomes of our studies suggest that targeting SLAMF6 is a potential therapeutic strategy.

20 January 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
BDBoaz Job van Driel
Boaz Job van Driel
GLGongxian Liao
Gongxian Liao
PEPablo Engel
Pablo Engel
CTCox Terhorst
Cox Terhorst
The SLAMF Family (SLAMF) of cell surface glycoproteins is comprised of nine glycoproteins and whilst SLAMF1, 3, 5, 6, 7, 8, 9 are self-ligand receptors, SLAMF2 and SLAMF4 interact with each other. Their interactions induce signal transduction networks in trans, thereby shaping immune cell-cell communications. Collectively, these receptors modulate a wide range of functions, such as myeloid cell and lymphocyte development and, T and B cell responses to microbes and parasites. In addition, several SLAMF receptors serve as microbial sensors, which either positively or negatively modulate the function of macrophages, dendritic cells, neutrophils and NK cells in response to microbial challenges. The SLAMF receptor-microbe interactions contribute both to intracellular microbicidal activity as well as to migration of phagocytes to the site of inflammation. In this review, we describe the current knowledge on how the SLAMF receptors and their specific adapters SAP and EAT-2 regulate innate and adaptive immune responses to microbes.